***Background.*** Global elimination of onchocerciasis and lymphatic filariasis is targeted for 2020 through mass drug administration. Given the potential for the development of drug resistance and the ongoing problem of co-incident *Loa loa* infection in Central Africa, the need for new orally available macro- and micro-filaricides has never been greater. The genomes and transcriptomes of *L. loa (Ll)*, *W. bancrofti (Wb), B. malayi (Bm) and O. volvulus*(Ov), revealed that each of these filarial parasites express protein kinases with significant homology to human kinase targets (SRC, Raf, mTOR, and c-Abl) that already have orally available FDA-approved inhibitors.

***Methods.*** The kinase inhibitors dasatinib, sorafenib, temsirolimus, imatinib, and nilotinib were tested over a wide dose range (100nM-100uM) on *Bm* adult males, adult females and microfilariae (MF) *in vitro*. Survival was assessed daily over a 6 day period and IC50s were determined. Three-dimensional (3D) modeling was used to understand the interaction between these drugs and the filarial parasite targets.

***Results.*** The antifilarial effects of imatinib and its next generation sister drugs nilotinib and dasatinib (also targets SRC) on filarial c-Abl showed that the IC50 for adult males ranged from 10uM (dasatinib) to 48uM (nilotinib) to 58.3uM (imatinib) whereas the IC50 for MF ranged from 6uM (dasatinib) to 12 uM (imatinib) to 33 uM (nilotinib). The IC50 for sorafenib, an inhibitor to Raf and other protein kinases (PK) against adult males was 0.6uM and was lower against MF (0.17uM). Temsirolimus, an mTOR inhibitor, had IC50s against adult males ∼10uM and MF ∼4uM (still accruing data). Determining IC50s in adult female *Bm* for each drug is currently underway, but preliminary data suggest the levels needed to kill adult females is significantly lower than those for adult males. Additionally, 3D modeling of the SRC, Raf, mTOR, and c-Abl filarial homologues demonstrate how dasatinib, sorafinib, temsirolimus, and imatinib/nilotinib dock at the respective catalytic domains to inhibit activity.

***Conclusion.*** Repurposed, orally available PK inhibitors should be considered as novel macro- and microfilaricides. Given their known safety in humans, assessment of their efficacy in human filarial infections should be undertaken.
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